TXG 10x Genomics, Inc.
Company Analysis
Latest News
🔴 10x Genomics falls 4.2% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Casdin Capital Slashes 10x Genomics (TXG) Position by More Than Half
In a quarterly disclosure filed on August 14, 2026, life-sciences investor Casdin Capital revealed a significant reduction in its stake in 10x Genomics (TXG)....
🟢 10x Genomics rises 4.0% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
10x Genomics Loses Sequencing Patent Ruling, Threatening Market Standing
10x Genomics lost a significant patent dispute regarding its sequencing technology. The ruling impacts the company's intellectual property rights and genomics...
🟢 10x Genomics is trading 10.44% up today on positive melanoma-vaccine results
10x Genomics is trading 10.44% up at $61.44 as biotechnology shares rally following positive Phase 3 melanoma-vaccine results from Moderna and Merck. - The...
🟢 10x Genomics is trading 9.49% up today on positive melanoma vaccine results
10x Genomics is trading 9.49% up now at $60.07 as biotechnology shares rally on positive late-stage melanoma vaccine results from Moderna and Merck. - The...
🔴 10x Genomics is trading 4.34% down today as rising yields and oil pressure growth stocks
10x Genomics is trading 4.34% down at $55.47 as growth stocks retreat alongside a weaker Nasdaq and S&P 500. - Rising Treasury yields and higher oil prices...
🔴 10x Genomics is trading 4% down in pre-market as global risk-off sentiment pressures growth stocks
10x Genomics is trading 4.16% down now at $55.58 in pre-market amid broad risk-off sentiment affecting growth-oriented stocks. - No clear company-specific...
🟢 10x Genomics is trading 4.4% up today — no clear catalyst identified
10x Genomics is trading 4.4% up at $58.58, with no clear company-specific catalyst identified. - No clear company-specific announcement or reliable news...
🟢 10x Genomics is trading 4.6% up in pre-market after Canaccord and Piper Sandler raised targets
10x Genomics is trading 4.6% up at $61.15 after analysts raised their price targets following the company’s second-quarter results. - Canaccord raised its...
10x Genomics Rides an Atera-Fueled Rally Past $57 — But Can a 40-Unit Shipment Cap Justify the Hype?
Shares of 10x Genomics surged 10.3% to $57.39 on Monday, extending a post-earnings rally that has lifted the stock roughly 22% in three trading sessions. The...
🟢 10x Genomics is trading 10% up today after Canaccord raised its price target to $60
10x Genomics is trading at $57.39 (+10.30%) after Canaccord raised its price target to $60 from $50 and Piper Sandler lifted its target to $47 from $42. - The...
🟢 10x Genomics is trading 5% up today after raising full-year 2026 guidance
10x Genomics is trading at $54.80 (+5.32%) as it extends its August 7, 2026 post-earnings rally after raising full-year 2026 guidance. - Second-quarter...
🟢 10x Genomics is trading 5% up today after raising 2026 revenue guidance
10x Genomics is trading 5.16% up now at $47.89 after its August 6 earnings beat revenue expectations and management raised full-year 2026 revenue guidance. -...
🔴 10x Genomics is trading 4.93% down in pre-market after investors focused on Atera transition
10x Genomics is trading at $43.35 (-4.93%) after August 6, 2026 release triggered a negative after-hours reaction despite revenue and adjusted-loss beats;...
🔴 10x Genomics is trading 4.7% down today in after-hours trading after rising expenses
10x Genomics is trading 4.7% down at $43.45 in after-hours trading after investors may be emphasizing slower reported growth and higher expenses despite raised...
10x Genomics' second quarter 2026 revenue of $151M beat estimates while narrowing its net loss
10x Genomics reported second quarter 2026 revenue of $151.0 million, exceeding analyst estimates of $146.67 million. While reported revenue declined...
🔴 10x Genomics is trading 4.5% down today ahead of Q2 2026 results
10x Genomics is trading 4.5% down at $45.32, with pre-earnings positioning and valuation concerns the most likely immediate pressures ahead of its Q2 2026...
10x Genomics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect 10x Genomics to report Q2 2026 revenue of $146.67 million and a consensus EPS loss of $0.23, with the stock’s current price of $47.27 trading...
🟢 10x Genomics is trading 4.1% up today as risk sentiment improves after sector-led pullback
10x Genomics is trading at $49.20 (4.1%) up in pre-market as the stock rebounds from a recent biotech-led pullback. • The move appears driven by firmer index...